European Commission Approves Praxbind for Reversing Dabigatran Anticoagulation

Strategic Insights -

The European Commission has approved Praxbind (idarucizumab), a treatment for reversing the anticoagulant effects of Pradaxa (dabigatran etexilate) in emergency surgery, urgent procedures, or life-threatening or uncontrolled bleeding situations. Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be approved in the European Union.

Key Takeaways:

  • Idarucizumab is a humanized antibody fragment designed to specifically bind to dabigatran molecules, neutralizing their anticoagulant effect.
  • The approval is based on data from healthy volunteers and an interim analysis of the RE-VERSE AD clinical study, which showed immediate and sustained reversal effects within minutes of administration.
  • Reversal was complete and sustained for a minimum of 12 hours in almost all patients, with no safety concerns or prothrombotic signals observed in over 200 volunteers and 123 patients from REVERSE-AD.
  • Idarucizumab is the first specific reversal agent for a NOAC to be approved in the European Union and has already been approved by the US Food and Drug Administration in October 2015.
  • Boehringer Ingelheim plans to make idarucizumab available as widely as possible and will launch it in European Union countries as soon as national requirements allow.
  • Idarucizumab was discovered and developed by Boehringer Ingelheim scientists, with the research program initiated in 2009.
  • The RE-VERSE AD global phase III patient study is ongoing to capture further data on the efficacy and safety profile of idarucizumab, which has been enrolling patients in over 35 countries since May 2014.
  • Idarucizumab is approved for use in adult patients treated with dabigatran when rapid reversal of its anticoagulant effects is required.

Statistics:

  • Over 5 million patient-years of clinical experience with dabigatran have been recorded in all licensed indications worldwide.
  • Dabigatran has been in the market for more than 7 years and is approved in over 100 countries.
  • Idarucizumab was administered in a dose of 5 grams to healthy volunteers and patients in the clinical study, resulting in immediate and sustained reversal of dabigatran's anticoagulant effect.
  • The RE-VERSE AD clinical study has enrolled patients in over 35 countries, capturing data on the efficacy and safety profile of idarucizumab in a global setting.

Sources:

  • European Commission press release
  • Boehringer Ingelheim press release
  • European Medicines Agency (EMA) press release
  • US Food and Drug Administration (FDA) press release
  • RE-VERSE AD clinical study (NCT 02104947, EudraCT 2013-004813-41)